Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | YWHAG | P61981 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | RGS12 | O14924 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4108699 | 0.86 | GAA (0.66) | GAAALDH1A1GFERHSP90AB1CYP4F2 | |
| SCHEMBL29446278 | 0.84 | GAA (0.72) | GAAALDH1A1GFERHSP90AB1CYP4F2 | |
| SCHEMBL3668882 | 0.84 | GAA (0.72) | GAAALDH1A1GFERHSP90AB1CYP4F2 | |
| SCHEMBL17689712 | 0.83 | YWHAG (0.50) | GAAALDH1A1GFERCYP4F2CYP4A11 | |
| SCHEMBL13211726 | 0.83 | ALDH1A1 (0.53) | GAAALDH1A1GFERHSP90AB1CYP4F2 | |
| Methyl Alcohol SCHEMBL27946196 | 0.82 | GAA (0.70) | GAAALDH1A1GFERHSP90AB1CYP4F2 | |
| Potassium Ion SCHEMBL7994403 | 0.81 | GAA (0.59) | GAAALDH1A1GFERHSP90AB1CYP4F2 | |
| SCHEMBL334348 | 0.81 | GAA (0.63) | GAAALDH1A1GFERHSP90AB1CYP4F2 | |
| SCHEMBL8146212 | 0.81 | GAA (0.63) | GAAALDH1A1GFERHSP90AB1CYP4F2 | |
| SCHEMBL2981679 | 0.79 | GAA (0.61) | GAAALDH1A1GFERHSP90AB1CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490047-B1 | CERTAIN PHARMACEUTICALLY USEFUL SUBSTITUTED AMINOALKYL HETEROCYCLES | SMITHKLINE BEECHAM CORP (US) | 2009-12-30 | — | — | EP | disclosed |
| EP-1511483-A4 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7323494-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323494-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323494-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1490047-A4 | CERTAIN PHARMACEUTICALLY USEFUL SUBSTITUTED AMINOALKYL HETEROCYCLES | SMITHKLINE BEECHAM CORP (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20050171084-A1 | Methods of treatment with lxr modulators | SMITHKLINE BEECHAM CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-20050165045-A1 | Compounds and methods | GLAXOSMITHKLINE LLC | 2005-07-28 | — | — | US | disclosed |
| EP-1511483-A2 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-09 | — | — | EP | disclosed |
| EP-1490047-A2 | CERTAIN PHARMACEUTICALLY USEFUL SUBSTITUTED AMINOALKYL HETEROCYCLES | SmithKline Beecham Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082192-A2 | CERTAIN PHARMACEUTICALLY USEFUL SUBSTITUTED AMINOALKYL HETEROCYCLES | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082198-A2 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165045-A1 | Compounds and methods | NR1H3, NR1H2, PPARA | GAA 1162/4885ALDH1A1 1291/4885GFER 1965/4885 |
| US-20050171084-A1 | Methods of treatment with lxr modulators | NR1H2, NR1H3, NR1H4 | GAA 2709/4885ALDH1A1 3430/4885GFER 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.